In vivo study revealed that CXB-BLs treatment mitigates LPS-induced AD through improving the memory via its AChE inhibitory effect and inhibiting neuro-inflammation and neuro-degeneration through suppressing TLR4 and IL-1β. This evidence concerns the gene IL1B and Alzheimer disease.